New four-way broiler breeder vaccine builds on success of Maternavac name

An interview with Kalen Cookson, DVM, MAM, Director of Clinical Research, Zoetis
calendar icon 28 September 2020
clock icon 5 minute read

Q: What about protection against reovirus with the new four-way vaccine?

KC: Seroconversion in the comparative study demonstrated that Poulvac Maternavac 4 and one of the three competitor vaccines gave the highest titers for reovirus.

We’ve taken great care to balance the IBDV and reovirus antigens in Poulvac Maternavac 4 because we’ve found during vaccine development that if there’s an imbalance, the reovirus titer response tends to be too low.

Q: Is there anything unique about the new four-way compared to comparable products?

KC: Yes. The NDV antigen in the vaccine is the Kimber strain, and that’s unique. The Kimber strain is highly immunogenic and is important in areas where NDV has become a serious threat to commercial flocks. Besides protecting hens, maternal antibodies for NDV passed on by hens should help reduce reactions to live NDV vaccines given in the hatchery to broiler progeny.

Q: Let’s talk about the infectious bronchitis component. Why did Zoetis opt for the Massachusetts strain but did not also include an Arkansas strain?

KC: When pullets are properly primed with a live Arkansas vaccine — as most are — there is little benefit to adding an Arkansas IBV antigen into the inactivated four-way products.5 This allows us to invest more in antigens that directly benefit the progeny.

Q: What can producers expect from Poulvac Maternavac 4?

KC: They can expect the vaccine will help establish a strong foundation of immunity against four very costly diseases of poultry. Strong immunity is especially important nowadays with the increase in “no antibiotics ever” production since viruses predispose to bacterial infections.

Notes: Treatments within a column that share a letter are not significantly different (P ≤ 0.05). B:BW is the bursa to bodyweight ratio.

Q: What about protection against reovirus with the new four-way vaccine?

KC: Seroconversion in the comparative study demonstrated that Poulvac Maternavac 4 and one of the three competitor vaccines gave the highest titers for reovirus.

We’ve taken great care to balance the IBDV and reovirus antigens in Poulvac Maternavac 4 because we’ve found during vaccine development that if there’s an imbalance, the reovirus titer response tends to be too low.

Q: Is there anything unique about the new four-way compared to comparable products?

KC: Yes. The NDV antigen in the vaccine is the Kimber strain, and that’s unique. The Kimber strain is highly immunogenic and is important in areas where NDV has become a serious threat to commercial flocks. Besides protecting hens, maternal antibodies for NDV passed on by hens should help reduce reactions to live NDV vaccines given in the hatchery to broiler progeny.

Q: Let’s talk about the infectious bronchitis component. Why did Zoetis opt for the Massachusetts strain but did not also include an Arkansas strain?

KC: When pullets are properly primed with a live Arkansas vaccine — as most are — there is little benefit to adding an Arkansas IBV antigen into the inactivated four-way products.5 This allows us to invest more in antigens that directly benefit the progeny.

Q: What can producers expect from Poulvac Maternavac 4?

KC: They can expect the vaccine will help establish a strong foundation of immunity against four very costly diseases of poultry. Strong immunity is especially important nowadays with the increase in “no antibiotics ever” production since viruses predispose to bacterial infections.

Poultry Health Today

© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.